Full-Time

Associate Director

Digital Product Operations, Measurement & Reporting

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$188.1k - $254.4k/yr

Remote in USA

Remote

Bachelor's, Master's, PhD, Associate's, Incomplete

Category
Product (1)
Required Skills
LLM
Power BI
SharePoint
Data Visualization
Product Management
Tableau
JIRA
Confluence
Data Governance
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 3 years of Digital Product, Product Management, Product Leadership, Digital Transformation, Technology Strategy, or related experience; or a master's degree and 7 years of such experience; or a bachelor's degree and 9 years of such experience; or an associate's degree and 12 years of such experience; or a high school diploma/GED and 14 years of such experience.
  • At least 3 years of experience directly managing people and/or leadership experience leading teams, projects, or programs or directing the allocation of resources.
  • 7+ years of progressive experience in product operations, digital product management, product analytics, enterprise measurement, business reporting, digital transformation, technology strategy, or related disciplines.
  • Ownership of a complex, high-priority product, operating-model, measurement, or transformation problem space spanning multiple teams or organizational areas.
  • Experience shaping measurement strategy, maturity models, adoption frameworks, scorecards, executive dashboards, or reporting systems for product teams, operating models, or enterprise transformation efforts.
  • Expert understanding of product management practices, including roadmaps, OKRs, product charters, product strategy, discovery, prioritization, value measurement, lifecycle management, and product operating models.
  • Ability to integrate quantitative data, qualitative insights, artifact reviews, and stakeholder perspectives into clear findings, leadership-ready narratives, and actionable recommendations.
  • Strong analytical judgment, including the ability to distinguish activity, compliance, and output measures from meaningful indicators of adoption, maturity, value realization, team health, and impact.
  • Experience guiding senior cross-functional partners across product, technology, business, analytics, reporting, finance, operations, compliance, and enablement teams in complex enterprise environments.
  • Experience building or guiding dashboards, reporting mechanisms, scorecards, maturity assessments, or executive readouts using tools such as Power BI, Tableau, Jira Align, Jira, Confluence, SharePoint, ChatGPT, or similar platforms.
  • Ability to influence without formal authority, constructively challenge senior partners, align teams through ambiguity, and guide consequential trade-offs involving data, adoption, product maturity, and operating-model improvement.
  • Experience coaching product managers or cross-functional partners, codifying reusable practices, and contributing to product management communities, standards, playbooks, or enablement programs.
  • Comfort operating in ambiguity, defining new measurement approaches, managing dependencies across teams, and improving reporting practices over time.
Responsibilities
  • Lead the enterprise measurement strategy for Digital Product Operating Model adoption, product management maturity, team health, and product artifact quality across multiple teams and organizational areas.
  • Translate Product Management Hub priorities into a coherent measurement framework, maturity model, executive reporting approach, and roadmap for continuous improvement.
  • Define standards, dimensions, and indicators used to assess adoption, maturity, artifact quality, operating health, and realized value of product ways of working.
  • Ensure the measurement approach distinguishes activity metrics from meaningful signals of adoption, maturity, decision quality, user value, and enterprise impact.
  • Frame ambiguous measurement problems, test assumptions, and determine which signals merit investment, instrumentation, leadership attention, and operating-model change.
  • Own the strategy and evolution of Digital Product Operating Model dashboards, scorecards, reporting mechanisms, and executive readouts for monthly business reviews, quarterly business reviews, and other enterprise operating cadences.
  • Guide analytics, technology, reporting, and product-operations partners in building scalable, trusted reporting solutions.
  • Integrate quantitative data, qualitative field insights, artifact reviews, and leadership feedback into clear findings, trends, risks, and recommendations.
  • Create leadership-ready narratives for Product Management Hub leadership, the Vice President of Product Management, the Chief Technology Officer, technology leaders, and business leaders.
  • Use reporting to surface cross-product dependencies, adoption barriers, maturity gaps, and opportunities to improve Digital Product Operating Model effectiveness across the enterprise.
  • Lead the assessment approach for product management maturity across teams, including outcome orientation, roadmap quality, OKR quality, decision-making, discovery, prioritization, value measurement, and lifecycle management.
  • Identify recurring maturity gaps, anti-patterns, adoption friction, and capability needs across product teams, product groups, and business functions.
  • Partner with Digital Product Management Catalysts to incorporate field-based insights from embedded engagements and convert those insights into enterprise-level learning.
  • Translate maturity and artifact-quality findings into improved standards, playbooks, templates, training, accelerator workshops, coaching approaches, and enablement materials.
  • Embed Digital Product Operating Model measurement and reporting into enterprise operating rhythms so adoption progress, maturity trends, risks, and learning inform decision-making at the right cadence.
  • Guide senior partners across Product Operations, Product Management Catalysts, digital product leadership, technology, business, analytics, and reporting teams to align on measures, interpretation, and actions.
  • Recommend annual and quarterly focus areas for Digital Product Operating Model measurement, reporting, enablement, and operating-model improvement based on enterprise needs and evidence.
  • Use measurement insights to guide trade-offs about where to focus support, coaching, capability-building, product community investment, and leadership attention.
  • Build repeatable mechanisms that make Digital Product Operating Model measurement sustainable, scalable, and useful across multiple teams and organizational areas.
  • Ensure measurement decisions are grounded in fit-for-purpose data, sound instrumentation, defensible metrics, and clear interpretation of limitations.
  • Partner with technology, data, analytics, reporting, and platform teams to address data quality, access, privacy, security, regulatory, responsible-artificial-intelligence, and governance considerations.
  • Identify appropriate opportunities to use artificial-intelligence-native workflows, generative artificial intelligence, and automation to improve measurement, analysis, reporting, artifact review, and leadership-readout preparation.
  • Lead complex cross-functional work through clear communication, credible product judgment, and constructive challenge without relying on direct authority.
  • Influence senior partners across product, technology, business, analytics, reporting, and enablement functions to align on measurement strategy, adoption signals, and improvement actions.
  • Coach product managers and product-operations partners on measurement, maturity assessment, artifact quality, dashboard interpretation, and leadership storytelling.
  • Codify effective practices, reusable examples, and standards that strengthen product-management capability and the Digital Product Operating Model community.
  • Contribute to product-management norms and operating-model practices that reinforce outcome-centered, user-centered, data-informed product leadership.
Desired Qualifications
  • Experience in healthcare, biotechnology, or other regulated industries; candidates from high-tech, digital, consulting, or product-led organizations are also encouraged to apply.
  • Familiarity with artificial-intelligence-native product development, generative artificial-intelligence workflows, responsible-artificial-intelligence principles, and the evolving role of artificial intelligence in product management and product operations.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.